# Biogen’s Tau-Targeting Therapy Shows Greater Slowing of Alzheimer’s Decline After Two Years

Biogen reported that its tau-targeting antisense oligonucleotide continued to slow clinical decline in Alzheimer’s disease patients over a two-year period. The updated results, which analysts described as strengthening the case for late-stage development, showed a larger benefit than earlier data had indicated.

The therapy is designed to reduce production of tau protein, a key driver of neurodegeneration in Alzheimer’s. The new findings come from an ongoing clinical program and add to evidence that targeting tau may modify the course of the disease.

**Context for the life sciences:** Antisense oligonucleotides represent a precision approach to treating neurodegenerative diseases by directly interfering with the production of disease-related proteins. Tau pathology is a hallmark of Alzheimer’s and other tauopathies, making it a high-priority target. Positive long-term data from Biogen’s program could encourage further investment in RNA-based therapies for brain disorders and expand the toolkit for tackling conditions that currently have limited treatment options.

Source: [original report](https://www.fiercebiotech.com/biotech/biogens-tau-therapy-drives-bigger-benefits-2-year-alzheimers-update)